Concepedia

Adel Kardosh

AK

Statistics

Publications

31

Citations

2.4K

H-Index

22

Active since

2003

Affiliations

University of Southern California(Current)

Southern California University for Professional Studies

Oregon Health & Science University

Stanford University

Roswell Park Comprehensive Cancer Center

Adel Kardosh is an author at University of Southern California specializing in medicine, oncology, and radiation oncology.

ORCID

Top concepts

Publications per year

2003–2025

31

Publications

31

Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial

Shukui Qin, Minshan Chen, Ann‐Lii Cheng et al. · The Lancet · 2023 · 415 citations · Full text

, , +8

Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial

Josep M. Llovet, Masatoshi Kudo, Philippe Merle et al. · The Lancet Oncology · 2023 · 364 citations

, , +10

Green tea polyphenols block the anticancer effects of bortezomib and other boronic acid–based proteasome inhibitors

Encouse B. Golden, Philip Y. Lam, Adel Kardosh et al. · Blood · 2009 · 283 citations

HIV-1 Protease Inhibitors Nelfinavir and Atazanavir Induce Malignant Glioma Death by Triggering Endoplasmic Reticulum Stress

Peter Pyrko, Adel Kardosh, Weijun Wang et al. · Cancer Research · 2007 · 140 citations · Full text

Aggravated Endoplasmic Reticulum Stress as a Basis for Enhanced Glioblastoma Cell Killing by Bortezomib in Combination with Celecoxib or Its Non-Coxib Analogue, 2,5-Dimethyl-Celecoxib

Adel Kardosh, Encouse B. Golden, Peter Pyrko et al. · Cancer Research · 2008 · 136 citations

1–5 of 31